Pediatric Hematologist/Oncologist (Child Cancer Specialist)
I am board-certified in general pediatrics and pediatric hematology and oncology at UF Health. My primary focus is the multidisciplinary treatment of pediatric solid tumors, particularly sarcomas of the bone and soft tissue. I also have a special interest in pediatric palliative care.
I am an active participant in several national professional societies and committees, including the Children’s Oncology Group, American Society of Pediatric Hematology/Oncology, American Society of Hematology, Connective Tissue Oncology Society and STOP Children’s Cancer.
In my clinical practice, I integrate translational research focused on targeted radionuclide therapies for osteosarcoma. I collaborate with colleagues across UF Veterinary Medicine, Biomedical Engineering, Chemistry, Materials Science and Engineering, and Radiation Oncology. My direct collaboration with pediatric oncology colleagues throughout Florida has also contributed to Phase I clinical trials for pediatric cancer patients across the state.
I joined UF in 2009 from Nationwide Children’s Hospital and The Ohio State University College of Medicine, where I completed a fellowship in pediatric hematology and oncology. I completed my pediatric residency training at Children’s Hospital of Monmouth in New Jersey, where I also served as chief resident.
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
See all insurancesThe purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food & Drug Administration (FDA), or any other…
This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to…
The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food & Drug…
GAINESVILLE, Fla. — Sawyer Bozeman has a simple hope for fifth grade: that his friends will be in his class. Despite the seriousness of his diagnosis, Sawyer,…
September 12, 2024
GAINESVILLE, Fla. — Eight years ago, Jennifer Arrington was simultaneously planning her unborn son’s funeral and her own. Diagnosed with a rare pediatric…
College of Medicine, UF Health Cancer Institute, +2 more
